CN103276062A - 作为诊断标记物的外来体相关微rna - Google Patents
作为诊断标记物的外来体相关微rna Download PDFInfo
- Publication number
- CN103276062A CN103276062A CN2013101656263A CN201310165626A CN103276062A CN 103276062 A CN103276062 A CN 103276062A CN 2013101656263 A CN2013101656263 A CN 2013101656263A CN 201310165626 A CN201310165626 A CN 201310165626A CN 103276062 A CN103276062 A CN 103276062A
- Authority
- CN
- China
- Prior art keywords
- mirna
- cancer
- mir
- exosome
- carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108700011259 MicroRNAs Proteins 0.000 title claims abstract description 385
- 239000002679 microRNA Substances 0.000 title claims description 365
- 239000003550 marker Substances 0.000 title claims description 16
- 210000001808 exosome Anatomy 0.000 title abstract description 200
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 258
- 201000011510 cancer Diseases 0.000 claims abstract description 175
- 238000000034 method Methods 0.000 claims abstract description 116
- 239000012472 biological sample Substances 0.000 claims abstract description 43
- 239000000523 sample Substances 0.000 claims description 108
- 238000001228 spectrum Methods 0.000 claims description 35
- 238000000926 separation method Methods 0.000 claims description 27
- 108091033319 polynucleotide Proteins 0.000 claims description 24
- 102000040430 polynucleotide Human genes 0.000 claims description 24
- 239000002157 polynucleotide Substances 0.000 claims description 24
- 230000008569 process Effects 0.000 claims description 23
- 210000002966 serum Anatomy 0.000 claims description 23
- 230000027455 binding Effects 0.000 claims description 16
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 14
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- 108091026807 MiR-214 Proteins 0.000 claims description 12
- 239000000090 biomarker Substances 0.000 claims description 12
- 108091058688 miR-141 stem-loop Proteins 0.000 claims description 11
- 108091074450 miR-200c stem-loop Proteins 0.000 claims description 11
- 108091059199 miR-200a stem-loop Proteins 0.000 claims description 10
- 108091089775 miR-200b stem-loop Proteins 0.000 claims description 10
- 108091062762 miR-21 stem-loop Proteins 0.000 claims description 10
- 108091041631 miR-21-1 stem-loop Proteins 0.000 claims description 10
- 108091044442 miR-21-2 stem-loop Proteins 0.000 claims description 10
- 108091028141 MiR-203 Proteins 0.000 claims description 9
- 108091062154 Mir-205 Proteins 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 210000002381 plasma Anatomy 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 206010003445 Ascites Diseases 0.000 claims description 5
- 238000002270 exclusion chromatography Methods 0.000 claims description 5
- 210000004910 pleural fluid Anatomy 0.000 claims description 5
- 206010036790 Productive cough Diseases 0.000 claims description 4
- 210000003567 ascitic fluid Anatomy 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
- 239000008267 milk Substances 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- 235000013336 milk Nutrition 0.000 claims description 4
- 238000003753 real-time PCR Methods 0.000 claims description 4
- 210000003296 saliva Anatomy 0.000 claims description 4
- 210000003802 sputum Anatomy 0.000 claims description 4
- 208000024794 sputum Diseases 0.000 claims description 4
- 210000001138 tear Anatomy 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 102100032912 CD44 antigen Human genes 0.000 claims description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 3
- 239000010445 mica Substances 0.000 claims description 3
- 229910052618 mica group Inorganic materials 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 abstract description 27
- 230000002411 adverse Effects 0.000 abstract description 3
- 230000035935 pregnancy Effects 0.000 abstract description 3
- 201000009030 Carcinoma Diseases 0.000 description 88
- 210000004027 cell Anatomy 0.000 description 84
- 206010061535 Ovarian neoplasm Diseases 0.000 description 54
- 206010033128 Ovarian cancer Diseases 0.000 description 46
- 230000014509 gene expression Effects 0.000 description 43
- 108090000623 proteins and genes Proteins 0.000 description 43
- 206010039491 Sarcoma Diseases 0.000 description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 34
- 201000010099 disease Diseases 0.000 description 33
- 208000032839 leukemia Diseases 0.000 description 32
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 25
- 238000004393 prognosis Methods 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 21
- 201000001441 melanoma Diseases 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 238000011160 research Methods 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 238000005516 engineering process Methods 0.000 description 17
- 238000002560 therapeutic procedure Methods 0.000 description 16
- 238000011282 treatment Methods 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 238000002493 microarray Methods 0.000 description 14
- 210000002826 placenta Anatomy 0.000 description 14
- 230000008859 change Effects 0.000 description 13
- 108020004999 messenger RNA Proteins 0.000 description 13
- 210000004881 tumor cell Anatomy 0.000 description 13
- 238000010606 normalization Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 11
- 208000009956 adenocarcinoma Diseases 0.000 description 10
- 230000000295 complement effect Effects 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 230000002018 overexpression Effects 0.000 description 10
- 206010006187 Breast cancer Diseases 0.000 description 9
- 208000026310 Breast neoplasm Diseases 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 208000003747 lymphoid leukemia Diseases 0.000 description 8
- 210000005259 peripheral blood Anatomy 0.000 description 8
- 239000011886 peripheral blood Substances 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 241000282898 Sus scrofa Species 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 208000020816 lung neoplasm Diseases 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 108091070501 miRNA Proteins 0.000 description 7
- 230000002611 ovarian Effects 0.000 description 7
- MEOVPKDOYAIVHZ-UHFFFAOYSA-N 2-chloro-1-(1-methylpyrrol-2-yl)ethanol Chemical compound CN1C=CC=C1C(O)CCl MEOVPKDOYAIVHZ-UHFFFAOYSA-N 0.000 description 6
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 206010060862 Prostate cancer Diseases 0.000 description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 6
- 238000003491 array Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 208000015124 ovarian disease Diseases 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000000630 rising effect Effects 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 208000009458 Carcinoma in Situ Diseases 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 208000007054 Medullary Carcinoma Diseases 0.000 description 5
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 5
- 206010036600 Premature labour Diseases 0.000 description 5
- 108010051489 calin Proteins 0.000 description 5
- 201000010989 colorectal carcinoma Diseases 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 210000001161 mammalian embryo Anatomy 0.000 description 5
- 238000001819 mass spectrum Methods 0.000 description 5
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000010208 microarray analysis Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 238000011275 oncology therapy Methods 0.000 description 5
- 210000005059 placental tissue Anatomy 0.000 description 5
- 208000026440 premature labor Diseases 0.000 description 5
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 5
- 206010058354 Bronchioloalveolar carcinoma Diseases 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 201000010881 cervical cancer Diseases 0.000 description 4
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 210000001163 endosome Anatomy 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 210000004276 hyalin Anatomy 0.000 description 4
- 201000004933 in situ carcinoma Diseases 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 208000025113 myeloid leukemia Diseases 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 208000031223 plasma cell leukemia Diseases 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 208000000649 small cell carcinoma Diseases 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 240000005020 Acaciella glauca Species 0.000 description 3
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 3
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 3
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 3
- 208000006332 Choriocarcinoma Diseases 0.000 description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010053574 Immunoblastic lymphoma Diseases 0.000 description 3
- 206010027336 Menstruation delayed Diseases 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 201000001542 Schneiderian carcinoma Diseases 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 3
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 3
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 201000003914 endometrial carcinoma Diseases 0.000 description 3
- 210000004696 endometrium Anatomy 0.000 description 3
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 206010024627 liposarcoma Diseases 0.000 description 3
- 208000037841 lung tumor Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000003864 performance function Effects 0.000 description 3
- 230000000505 pernicious effect Effects 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 108091007428 primary miRNA Proteins 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 235000003499 redwood Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000008054 signal transmission Effects 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 238000010183 spectrum analysis Methods 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 201000000498 stomach carcinoma Diseases 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000000439 tumor marker Substances 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 241000321096 Adenoides Species 0.000 description 2
- 208000035805 Aleukaemic leukaemia Diseases 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000013165 Bowen disease Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010063045 Effusion Diseases 0.000 description 2
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- 206010055690 Foetal death Diseases 0.000 description 2
- 208000008999 Giant Cell Carcinoma Diseases 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 206010024218 Lentigo maligna Diseases 0.000 description 2
- 108091033433 MiR-191 Proteins 0.000 description 2
- 206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 206010029488 Nodular melanoma Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 241000272458 Numididae Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 2
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 2
- 208000037273 Pathologic Processes Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000003107 Premature Rupture Fetal Membranes Diseases 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 208000012018 Yolk sac tumor Diseases 0.000 description 2
- 206010000583 acral lentiginous melanoma Diseases 0.000 description 2
- 208000036676 acute undifferentiated leukemia Diseases 0.000 description 2
- 210000002534 adenoid Anatomy 0.000 description 2
- 208000008524 alveolar soft part sarcoma Diseases 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 208000016894 basaloid carcinoma Diseases 0.000 description 2
- 201000000450 basaloid squamous cell carcinoma Diseases 0.000 description 2
- 208000003373 basosquamous carcinoma Diseases 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 2
- 201000009480 botryoid rhabdomyosarcoma Diseases 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 201000011050 comedo carcinoma Diseases 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 208000001991 endodermal sinus tumor Diseases 0.000 description 2
- 108010032819 exoribonuclease II Proteins 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000003328 fibroblastic effect Effects 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 210000001865 kupffer cell Anatomy 0.000 description 2
- 208000003849 large cell carcinoma Diseases 0.000 description 2
- 208000011080 lentigo maligna melanoma Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000000014 lung giant cell carcinoma Diseases 0.000 description 2
- 201000000966 lung oat cell carcinoma Diseases 0.000 description 2
- 208000025036 lymphosarcoma Diseases 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108091091751 miR-17 stem-loop Proteins 0.000 description 2
- 108091007426 microRNA precursor Proteins 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 201000006894 monocytic leukemia Diseases 0.000 description 2
- 201000000032 nodular malignant melanoma Diseases 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 201000010198 papillary carcinoma Diseases 0.000 description 2
- 230000009054 pathological process Effects 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 201000011461 pre-eclampsia Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 208000029817 pulmonary adenocarcinoma in situ Diseases 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000003728 serous cell Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 208000028210 stromal sarcoma Diseases 0.000 description 2
- 208000030457 superficial spreading melanoma Diseases 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000009871 tenuigenin Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- 239000000107 tumor biomarker Substances 0.000 description 2
- 208000008662 verrucous carcinoma Diseases 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 108020005096 28S Ribosomal RNA Proteins 0.000 description 1
- PHIYHIOQVWTXII-UHFFFAOYSA-N 3-amino-1-phenylpropan-1-ol Chemical compound NCCC(O)C1=CC=CC=C1 PHIYHIOQVWTXII-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 108010013043 Acetylesterase Proteins 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 102000003916 Arrestin Human genes 0.000 description 1
- 108090000328 Arrestin Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010004173 Basophilia Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 241000283730 Bos primigenius Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 206010008583 Chloroma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000019399 Colonic disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 101100239628 Danio rerio myca gene Proteins 0.000 description 1
- 102000012804 EPCAM Human genes 0.000 description 1
- 101150084967 EPCAM gene Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010057649 Endometrial sarcoma Diseases 0.000 description 1
- 206010014958 Eosinophilic leukaemia Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 208000009331 Experimental Sarcoma Diseases 0.000 description 1
- 102000047351 Exportin-5 Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 241000282816 Giraffa camelopardalis Species 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000017662 Hodgkin disease lymphocyte depletion type stage unspecified Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000847058 Homo sapiens Exportin-5 Proteins 0.000 description 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 210000005131 Hürthle cell Anatomy 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 206010023256 Juvenile melanoma benign Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010053180 Leukaemia cutis Diseases 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 244000278243 Limnocharis flava Species 0.000 description 1
- 235000003403 Limnocharis flava Nutrition 0.000 description 1
- 241000090179 Lorio Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 108091093082 MiR-146 Proteins 0.000 description 1
- 108091033773 MiR-155 Proteins 0.000 description 1
- 108091028108 MiR-212 Proteins 0.000 description 1
- 108091030146 MiRBase Proteins 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 102100021010 Nucleolin Human genes 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 241001278385 Panthera tigris altaica Species 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 208000019262 Pilomatrix carcinoma Diseases 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 240000002825 Solanum vestissimum Species 0.000 description 1
- 235000018259 Solanum vestissimum Nutrition 0.000 description 1
- -1 Streptomycin sulphates Chemical class 0.000 description 1
- 101150057140 TACSTD1 gene Proteins 0.000 description 1
- 108700031126 Tetraspanins Proteins 0.000 description 1
- 102000043977 Tetraspanins Human genes 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- LUTSRLYCMSCGCS-BWOMAWGNSA-N [(3s,8r,9s,10r,13s)-10,13-dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,16-decahydrocyclopenta[a]phenanthren-3-yl] acetate Chemical compound C([C@@H]12)C[C@]3(C)C(=O)CC=C3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)C)C1 LUTSRLYCMSCGCS-BWOMAWGNSA-N 0.000 description 1
- 208000006336 acinar cell carcinoma Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000017488 activation-induced cell death of T cell Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 208000006431 amelanotic melanoma Diseases 0.000 description 1
- 230000002707 ameloblastic effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000010983 breast ductal carcinoma Diseases 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000023402 cell communication Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 201000011063 cribriform carcinoma Diseases 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 238000007418 data mining Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 208000010932 epithelial neoplasm Diseases 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 235000003869 genetically modified organism Nutrition 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 201000007574 granular cell carcinoma Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 208000017750 granulocytic sarcoma Diseases 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007417 hierarchical cluster analysis Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003228 intrahepatic bile duct Anatomy 0.000 description 1
- 101150044508 key gene Proteins 0.000 description 1
- 108091042844 let-7i stem-loop Proteins 0.000 description 1
- 230000000610 leukopenic effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 201000010953 lymphoepithelioma-like carcinoma Diseases 0.000 description 1
- 206010061526 malignant mesenchymoma Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000000684 melanotic effect Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 108091064157 miR-106a stem-loop Proteins 0.000 description 1
- 108091037426 miR-152 stem-loop Proteins 0.000 description 1
- 108091027943 miR-16 stem-loop Proteins 0.000 description 1
- 108091044046 miR-17-1 stem-loop Proteins 0.000 description 1
- 108091065423 miR-17-3 stem-loop Proteins 0.000 description 1
- 108091086416 miR-192 stem-loop Proteins 0.000 description 1
- 108091048308 miR-210 stem-loop Proteins 0.000 description 1
- 108091053935 miR-212 stem-loop Proteins 0.000 description 1
- 108091028397 miR-212-1 stem-loop Proteins 0.000 description 1
- 108091028945 miR-212-2 stem-loop Proteins 0.000 description 1
- 108091035328 miR-217 stem-loop Proteins 0.000 description 1
- 108091032902 miR-93 stem-loop Proteins 0.000 description 1
- 238000012775 microarray technology Methods 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- NKAAEMMYHLFEFN-UHFFFAOYSA-M monosodium tartrate Chemical compound [Na+].OC(=O)C(O)C(O)C([O-])=O NKAAEMMYHLFEFN-UHFFFAOYSA-M 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 201000005987 myeloid sarcoma Diseases 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- 208000014761 nasopharyngeal type undifferentiated carcinoma Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 208000029809 non-keratinizing sinonasal squamous cell carcinoma Diseases 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108010044762 nucleolin Proteins 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 201000007426 ovarian cystadenocarcinoma Diseases 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- BLFWHYXWBKKRHI-JYBILGDPSA-N plap Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@@H](N)CCC(O)=O BLFWHYXWBKKRHI-JYBILGDPSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 235000019353 potassium silicate Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000985 reactive dye Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 238000011309 routine diagnosis Methods 0.000 description 1
- 208000014212 sarcomatoid carcinoma Diseases 0.000 description 1
- 208000004259 scirrhous adenocarcinoma Diseases 0.000 description 1
- 201000008157 scrotal carcinoma Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 201000002078 skin pilomatrix carcinoma Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 208000011584 spitz nevus Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- 201000010033 subleukemic leukemia Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 208000022810 undifferentiated (embryonal) sarcoma Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G07—CHECKING-DEVICES
- G07F—COIN-FREED OR LIKE APPARATUS
- G07F17/00—Coin-freed apparatus for hiring articles; Coin-freed facilities or services
- G07F17/32—Coin-freed apparatus for hiring articles; Coin-freed facilities or services for games, toys, sports, or amusements
- G07F17/3202—Hardware aspects of a gaming system, e.g. components, construction, architecture thereof
- G07F17/3204—Player-machine interfaces
- G07F17/3211—Display means
-
- G—PHYSICS
- G07—CHECKING-DEVICES
- G07F—COIN-FREED OR LIKE APPARATUS
- G07F17/00—Coin-freed apparatus for hiring articles; Coin-freed facilities or services
- G07F17/32—Coin-freed apparatus for hiring articles; Coin-freed facilities or services for games, toys, sports, or amusements
- G07F17/3244—Payment aspects of a gaming system, e.g. payment schemes, setting payout ratio, bonus or consolation prizes
- G07F17/3258—Cumulative reward schemes, e.g. jackpots
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95181207P | 2007-07-25 | 2007-07-25 | |
US60/951,812 | 2007-07-25 | ||
US5043808P | 2008-05-05 | 2008-05-05 | |
US61/050,438 | 2008-05-05 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880025224.0A Division CN101755208B (zh) | 2007-07-25 | 2008-07-25 | 作为诊断标记物的外来体相关微rna |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103276062A true CN103276062A (zh) | 2013-09-04 |
Family
ID=40281854
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2013101656263A Pending CN103276062A (zh) | 2007-07-25 | 2008-07-25 | 作为诊断标记物的外来体相关微rna |
CN200880025224.0A Active CN101755208B (zh) | 2007-07-25 | 2008-07-25 | 作为诊断标记物的外来体相关微rna |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880025224.0A Active CN101755208B (zh) | 2007-07-25 | 2008-07-25 | 作为诊断标记物的外来体相关微rna |
Country Status (11)
Country | Link |
---|---|
US (5) | US8216784B2 (de) |
EP (3) | EP2613149B1 (de) |
JP (3) | JP5156829B2 (de) |
CN (2) | CN103276062A (de) |
AU (1) | AU2008279016B2 (de) |
BR (1) | BRPI0807318B8 (de) |
CA (1) | CA2676113C (de) |
ES (1) | ES2420973T3 (de) |
GB (1) | GB2459228B (de) |
IL (3) | IL200028A (de) |
WO (1) | WO2009015357A1 (de) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105368931A (zh) * | 2015-10-15 | 2016-03-02 | 天津市泌尿外科研究所 | 尿液中exosome源性miRNAs生物标记物的检测方法 |
CN108753964A (zh) * | 2018-06-04 | 2018-11-06 | 谢丽 | 一种用于非小细胞肺癌诊断及转移预警的试剂盒 |
Families Citing this family (176)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8021847B2 (en) | 2004-06-02 | 2011-09-20 | Proxy Life Science Holdings, Inc. | Microvesicle-based compositions and methods |
CA2609260A1 (en) * | 2004-06-02 | 2005-12-22 | Sourcepharm, Inc. | Rna-containing microvesicles and methods therefor |
ES2526787T3 (es) | 2006-01-05 | 2015-01-15 | The Ohio State University Research Foundation | Métodos basados en microARN para el diagnóstico de cánceres de colon, páncreas y estómago |
EP3517151B1 (de) * | 2006-03-09 | 2021-04-21 | Aethlon Medical, Inc. | Extrakorporale entfernung von mikrovesikulären teilchen |
EP2371971B1 (de) | 2006-03-20 | 2013-11-27 | The Ohio State University Research Foundation | Mikro-RNA-Fingerabdrücke während humaner Megakaryozytopoiese |
WO2008136971A1 (en) * | 2007-04-30 | 2008-11-13 | The Ohio State University Research Foundation | Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis |
EP2613149B1 (de) * | 2007-07-25 | 2014-09-17 | University Of Louisville Research Foundation, Inc. | Exosomassoziierte microRNA als Diagnosemarker |
EP2650383A1 (de) | 2007-08-03 | 2013-10-16 | The Ohio State University Research Foundation | Ultrakonservierte Bereiche zur Codierung von ncRNA |
EP2696203A3 (de) | 2007-08-16 | 2014-05-28 | The Royal Institution for the Advancement of Learning/McGill University | Tumorzellen-abgeleitete Mikrovesikel |
US20100255514A1 (en) * | 2007-08-16 | 2010-10-07 | The Royal Institution For The Advancement Of Learning/Mcgill University | Tumor cell-derived microvesicles |
AU2008296022B2 (en) * | 2007-09-06 | 2014-01-23 | The Ohio State University Research Foundation | MicroRNA signatures in human ovarian cancer |
ES2419129T3 (es) * | 2007-09-14 | 2013-08-19 | The Ohio State University Research Foundation | Expresión de miARN en microvesículas de sangre periférica humana y usos del mismo |
CN103937876B (zh) * | 2007-10-11 | 2016-08-17 | 俄亥俄州立大学研究基金会 | 用于诊断和治疗食管腺癌的方法和组合物 |
CN101424640B (zh) * | 2007-11-02 | 2012-07-25 | 江苏命码生物科技有限公司 | 血清中微小核糖核酸的检测方法和用于检测的试剂盒、生物芯片及其制作和应用方法 |
EP2234483A4 (de) | 2008-01-27 | 2011-04-27 | Rosetta Genomics Ltd | Verfahren und zusammensetzungen zur diagnose von schwangerschaftskomplikationen |
SG10201609507TA (en) * | 2008-02-01 | 2017-01-27 | Gen Hospital Corp | Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions |
AU2009219190A1 (en) * | 2008-02-28 | 2009-09-03 | The Ohio State University Research Foundation | MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of gastric cancer |
EP2294196A1 (de) * | 2008-06-06 | 2011-03-16 | Centre National de la Recherche Scientifique - CNRS | Verwendung des endolysosomalen systems und sezernierter vesikel (exosomenähnlich) bei behandlungen und diagnostik auf der basis kleiner rna sowie experimentelle untersuchung kleiner rna |
US9410956B1 (en) * | 2008-08-01 | 2016-08-09 | University Of South Florida | Micro-RNA profiling in ovarian cancer |
US9487837B2 (en) * | 2008-10-06 | 2016-11-08 | Morehouse School Of Medicine | Exosome-mediated diagnosis of hepatitis virus infections and diseases |
JP2012507300A (ja) | 2008-10-30 | 2012-03-29 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス | Rnaパターンを評価する方法 |
CN107254538A (zh) * | 2008-11-12 | 2017-10-17 | 卡里斯生命科学瑞士控股有限责任公司 | 使用外来体来确定表现型的方法和系统 |
CN101475984A (zh) * | 2008-12-15 | 2009-07-08 | 江苏命码生物科技有限公司 | 一种非小细胞肺癌检测标记物及其检测方法、相关生物芯片和试剂盒 |
JP2012514994A (ja) * | 2009-01-19 | 2012-07-05 | システミック・スコットランド・リミテッド | 非コードrna発現アッセイを用いた方法 |
CN102421916A (zh) * | 2009-04-21 | 2012-04-18 | 日本电气株式会社 | 用于评估癌症的方法 |
US20120077263A1 (en) * | 2009-06-05 | 2012-03-29 | Mayo Foundation For Medical Education And Research | Methods and materials for isolating exosomes |
ES2547715T3 (es) * | 2009-07-16 | 2015-10-08 | The General Hospital Corporation | Análisis de ácido nucleico |
CN101988062A (zh) * | 2009-07-30 | 2011-03-23 | 江苏命码生物科技有限公司 | 宫颈癌检测标记物及其检测方法、试剂盒和生物芯片 |
US8735074B2 (en) * | 2009-08-28 | 2014-05-27 | Asuragen, Inc. | MiRNA biomarkers of lung disease |
WO2011031892A1 (en) | 2009-09-09 | 2011-03-17 | The General Hospital Corporation | Use of microvesicles in analyzing kras mutations |
EP3461912B1 (de) | 2009-09-09 | 2022-07-13 | The General Hospital Corporation | Verwendung von mikrovesikeln bei der analyse von nukleinsäureprofilen |
TW201118178A (en) * | 2009-10-09 | 2011-06-01 | Baylor Res Inst | Identification of micrornas (miRNAs) in fecal samples as biomarkers for gastroenterological cancers |
EP2316972A1 (de) * | 2009-10-29 | 2011-05-04 | Deutsches Krebsforschungszentrum | Zirkulierende miRNAs als nichtinvasive Marker zur Diagnose und Abstufung bei Prostatakrebs |
CA2780222C (en) | 2009-11-04 | 2021-11-16 | Diamir, Llc | Methods of using small rna from bodily fluids for diagnosis and monitoring of neurodegenerative diseases |
CN101798594A (zh) * | 2009-11-13 | 2010-08-11 | 北京命码生科科技有限公司 | 检测牛乳质量的标志物、检测方法、生物芯片和试验盒 |
WO2011063324A2 (en) * | 2009-11-20 | 2011-05-26 | The General Hospital Corporation | Microfluidic systems for isolating microvesicles |
WO2011063382A1 (en) | 2009-11-23 | 2011-05-26 | The Ohio State University | Materials and methods useful for affecting tumor cell growth, migration and invasion |
EP2341145A1 (de) | 2009-12-30 | 2011-07-06 | febit holding GmbH | miRNA-Fingerabdruck für die Krankheitsdiagnose |
CN103237901B (zh) * | 2010-03-01 | 2016-08-03 | 卡里斯生命科学瑞士控股有限责任公司 | 用于治疗诊断的生物标志物 |
KR20130043104A (ko) * | 2010-04-06 | 2013-04-29 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | 질병용 순환 생물학적 지표들 |
EP2559442B1 (de) * | 2010-04-13 | 2017-12-06 | Jiangsu Mingma Biotech Co., Ltd | Verfahren zur regulierung des microrna-gehalts bei organismen und seine verwendung |
US20130203081A1 (en) * | 2010-04-13 | 2013-08-08 | Janusz Rak | Tumor cell-derived microvesicles |
WO2011156734A2 (en) * | 2010-06-11 | 2011-12-15 | Hitachi Chemical Co., Ltd. | Method of characterizing vascular diseases |
JP5755326B2 (ja) | 2010-06-11 | 2015-07-29 | 日立化成株式会社 | 腎機能の特徴を決定する方法 |
ES2624284T3 (es) * | 2010-07-07 | 2017-07-13 | Aethlon Medical Inc | Métodos para cuantificar exosomas |
WO2012031008A2 (en) | 2010-08-31 | 2012-03-08 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
CN101921759B (zh) * | 2010-09-08 | 2013-05-29 | 南京医科大学 | 一种与宫颈癌及其癌前病变相关的血清/血浆miRNA标志物及其应用 |
EP2446929A1 (de) * | 2010-10-27 | 2012-05-02 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Aus atheroprotektiven Endothelzellen abgeleitete Mikrovesikel zur Behandlung und Prävention von atherosklerotischen Leiden |
US20120107825A1 (en) | 2010-11-01 | 2012-05-03 | Winger Edward E | Methods and compositions for assessing patients with reproductive failure using immune cell-derived microrna |
EP2638057B1 (de) | 2010-11-10 | 2019-03-06 | Exosome Diagnostics, Inc. | Verfahren zur isolierung von nukleinsäure enthaltenden partikeln und extraktion von nukleinsäuren daraus |
EP2637673B1 (de) | 2010-11-12 | 2016-10-26 | The Ohio State University Research Foundation | Verfahren im Zusammenhang mit Mikro-RNA-21 und Inkongruenzbehebung in Kolorektalkrebs |
CA2817982C (en) | 2010-11-15 | 2020-06-30 | The Regents Of The University Of Michigan | Controlled release mucoadhesive systems |
JP2012125215A (ja) * | 2010-12-17 | 2012-07-05 | Osaka City Univ | 肝線維症の存在及び/又は肝線維症の重症度の判定方法、判定マーカー、判定用キット、肝線維症の治療の効果予測方法、効果予測マーカー、並びに効果予測用キット |
EP2505663A1 (de) * | 2011-03-30 | 2012-10-03 | IFOM Fondazione Istituto Firc di Oncologia Molecolare | Verfahren zur Identifizierung von symptomlosen Risikopatienten mit Lungenkrebs im Frühstadium durch die Erkennung von miRNAs in biologischen Flüssigkeiten |
AU2012245580B2 (en) | 2011-04-18 | 2017-07-20 | Diamir, Llc | miRNA-based universal screening test (UST) |
ES2744589T3 (es) * | 2011-05-11 | 2020-02-25 | Exosome Diagnostics Inc | Extracción de ácido nucleico de materiales biológicos heterogéneos |
WO2012170037A1 (en) | 2011-06-10 | 2012-12-13 | Hitachi Chemical Co., Ltd. | Vesicle capturing devices and methods for using same |
EP2723865B1 (de) * | 2011-06-21 | 2019-03-27 | Alnylam Pharmaceuticals, Inc. | VERFAHREN ZUR BESTIMMUNG DER AKTIVITÄT VON RNAi IN EINEM PATIENTEN |
US9771617B2 (en) * | 2011-06-27 | 2017-09-26 | Eisai R&D Management Co., Ltd. | Microrna biomarkers indicative of alzheimer's disease |
EP2739754A4 (de) * | 2011-08-05 | 2015-01-21 | Univ Louisville Res Found | Mikro-rna-biomarker |
AU2012294458A1 (en) * | 2011-08-08 | 2014-02-27 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarker compositions and methods |
AU2012323924A1 (en) * | 2011-10-14 | 2014-05-29 | The Ohio State University | Methods and materials related to ovarian cancer |
EP2584040A1 (de) * | 2011-10-17 | 2013-04-24 | Pharmahungary 2000 Kft. | Verbindungen zur Behandlung ischämischer Verletzungen |
US20140243240A1 (en) * | 2011-10-26 | 2014-08-28 | Georgetown University | microRNA EXPRESSION PROFILING OF THYROID CANCER |
WO2013063439A1 (en) * | 2011-10-27 | 2013-05-02 | University Of Louisville Research Foundation, Inc. | Characterizing melanoma |
US20140308212A1 (en) | 2011-11-07 | 2014-10-16 | University Of Louisville Research Foundation, Inc. | Edible plant-derived microvesicle compositions for diagnosis and treatment of disease |
EP4349343A3 (de) * | 2011-11-30 | 2024-10-16 | Jörn Bullerdiek | Expression von mirnas in plazentagewebe |
JP2015501843A (ja) | 2011-12-13 | 2015-01-19 | オハイオ・ステイト・イノベーション・ファウンデーション | miR−21およびmiR−29a、エキソソーム阻害、およびがん転移に関する方法および組成物 |
US9447471B2 (en) | 2011-12-29 | 2016-09-20 | Quest Diagnostics Investments Incorporated | Microrna profiling for diagnosis of dysplastic nevi and melanoma |
AU2013209477B2 (en) | 2012-01-20 | 2016-12-08 | The Ohio State University | Breast cancer biomarker signatures for invasiveness and prognosis |
WO2013125691A1 (ja) | 2012-02-23 | 2013-08-29 | 住友ベークライト株式会社 | テスト体液サンプルの分類方法 |
CA2870593A1 (en) * | 2012-04-16 | 2013-10-24 | Board Of Regents, The University Of Texas System | Detection of extracellular jcv micrornas |
WO2013155633A1 (en) * | 2012-04-19 | 2013-10-24 | Leong Hon Sing | Method for detecting or monitoring prostate cancer |
AU2013302526B2 (en) | 2012-08-15 | 2018-03-22 | The University Of Chicago | Exosome-based therapeutics against neurodegenerative disorders |
CA2879410C (en) * | 2012-08-20 | 2018-06-26 | National Cancer Center | Agent for treating cancer |
CN102864224A (zh) * | 2012-09-11 | 2013-01-09 | 南京大学 | 一种血清microRNAs试剂盒及其应用 |
WO2014041087A1 (en) | 2012-09-12 | 2014-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Muscle secretome and uses thereof |
WO2014059336A1 (en) | 2012-10-12 | 2014-04-17 | University Of Notre Dame Du Lac | Exosomes and diagnostic biomarkers |
US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
KR20150090072A (ko) * | 2012-10-23 | 2015-08-05 | 카리스 라이프 사이언스 스위스 홀딩스 게엠베하 | 압타머 및 이의 용도 |
EP2746406B1 (de) | 2012-12-18 | 2017-08-23 | Samsung Electronics Co., Ltd. | Zusammensetzung und Kit zur Diagnose von Brustkrebs mit miRNA im Vesikel und Verfahren zur Diagnose von Brustkrebs damit |
EP2935628B1 (de) | 2012-12-19 | 2018-03-21 | Caris Life Sciences Switzerland Holdings GmbH | Zusammensetzungen und verfahren für aptamer-screening |
US9086412B2 (en) * | 2012-12-31 | 2015-07-21 | University Of Louisville Research Foundation, Inc. | Extracellular vesicle-associated protein markers of cancer |
WO2014160032A1 (en) * | 2013-03-13 | 2014-10-02 | University Of Louisville Research Foundation, Inc. | Exosome-associated rna as a diagnostic marker |
DK2972193T3 (da) | 2013-03-13 | 2020-03-23 | Univ Miami | Fremgangsmåde til isolation og oprensning af mikrovesikler fra cellekultursupernatanter og biologiske fluider |
WO2014145612A1 (en) * | 2013-03-15 | 2014-09-18 | Ajay Goel | Tissue and blood-based mirna biomarkers for the diagnosis, prognosis and metastasis-predictive potential in colorectal cancer |
RU2644247C2 (ru) | 2013-03-15 | 2018-02-08 | Борд оф Риджентс, Дзе Юниверсити оф Тексас Систем | Использование биогенеза микрорнк в экзосомах для диагностики и лечения |
DE102013103447A1 (de) * | 2013-04-05 | 2014-10-09 | Bodo C. Melnik | Verfahren und Vorrichtung zur Herstellung kommerzieller Milch und Milch mit reduzierter biologischer Wirkung exosomaler Ribonukleinsäuren |
WO2014182330A1 (en) | 2013-05-06 | 2014-11-13 | Hitachi Chemical Company Ltd | Devices and methods for capturing target molecules |
US9213029B2 (en) | 2013-06-25 | 2015-12-15 | Samsung Electronics Co., Ltd. | Method for diagnosing breast cancer by detection of polymeric immunoglobulin receptor in vesicles isolated from patients |
US10301681B2 (en) * | 2013-08-06 | 2019-05-28 | Exosome Diagnostics, Inc. | Methods of treating a subject with a high gleason score prostate cancer |
WO2015045666A1 (ja) | 2013-09-25 | 2015-04-02 | 国立大学法人東京大学 | 流体デバイス、エキソソームの分析方法、生体分子分析方法及び生体分子検出方法 |
KR20150043937A (ko) | 2013-10-15 | 2015-04-23 | 삼성전자주식회사 | 개체의 간암 진단용 조성물, 개체의 간암 진단하는 방법 및 개체의 간암 진단에 필요한 정보를 얻는 방법 |
WO2015057806A1 (en) * | 2013-10-15 | 2015-04-23 | The Board Of Trustees Of The University Of Illinois | Serum mirnas for the prognosis of prostate cancer |
PL405648A1 (pl) | 2013-10-15 | 2015-04-27 | Warszawski Uniwersytet Medyczny | Sposób diagnozowania raka watrobowokomórkowego, zastosowanie markera mikroRNA do diagnozowania zmiany chorobowej w obrębie wątroby, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny |
JP6547625B2 (ja) | 2013-10-25 | 2019-07-24 | 凸版印刷株式会社 | 膜小胞回収デバイス、膜小胞回収方法、及び膜小胞分析方法 |
PL406033A1 (pl) | 2013-11-14 | 2015-05-25 | Warszawski Uniwersytet Medyczny | Sposób diagnozowania raka brodawkowatego tarczycy, zastosowanie markera mikroRNA do diagnozowania nowotworu tarczycy, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny |
ES2813699T3 (es) | 2013-11-18 | 2021-03-24 | Diamir Llc | Métodos de uso de miARN de fluidos corporales para la detección y monitoreo de la enfermedad de Parkinson (PD) |
FR3014198B1 (fr) * | 2013-12-03 | 2017-03-03 | Biomerieux Sa | Procede d'isolement d'exosomes |
KR101535737B1 (ko) * | 2014-01-09 | 2015-07-09 | 충남대학교산학협력단 | miRNA를 포함하는 자간전증 진단 및 치료용 조성물 |
WO2015108342A1 (ko) * | 2014-01-14 | 2015-07-23 | 최원철 | 루테리알의 형태특성을 이용한 암 예방제 또는 항암제의 스크리닝 방법 |
US10260105B2 (en) | 2014-02-18 | 2019-04-16 | Baylor Research Institute | MiR-320e and colorectal cancer |
EP3111212B1 (de) * | 2014-02-27 | 2018-08-29 | Board of Regents, The University of Texas System | Verfahren und zusammensetzungen zur isolierung von exosomen |
CN103937888B (zh) * | 2014-04-14 | 2016-08-17 | 上海交通大学 | 鉴别胃癌的血浆microRNA标志物的筛选与应用 |
CN103954770B (zh) * | 2014-04-25 | 2015-09-30 | 江南大学 | EVs-TRPC5在检测乳腺癌耐药程度中的应用 |
CN103993015B (zh) * | 2014-05-23 | 2016-04-27 | 山西医科大学 | 人类子痫前期发生相关的外周血白细胞miRNA标志物及其应用 |
KR102711760B1 (ko) * | 2014-06-12 | 2024-09-30 | 국립연구개발법인 고쿠리츠간켄큐센터 | 전립선암 검출 키트 또는 디바이스 및 검출 방법 |
EP3173143A4 (de) | 2014-07-24 | 2018-06-27 | Toppan Printing Co., Ltd. | Lipidmembranstruktur, immobilisierungsträger für lipidmembranstruktur und verfahren zur zellfusion |
KR101784714B1 (ko) | 2014-08-19 | 2017-10-12 | 주식회사 엠모니터 | 재발 난소암 진단 또는 난소암 재발 예측용 mirna 마커 및 그 용도 |
US20170298352A1 (en) | 2014-09-30 | 2017-10-19 | Research Institute at Nationwide Children's Hospit al | Compositions and methods for treating hepatic fibrosis |
WO2016057474A1 (en) * | 2014-10-06 | 2016-04-14 | Indiana University Research & Technology Corporation | Systems and methods for localized surface plasmon resonance biosensing |
RU2571507C1 (ru) * | 2014-10-09 | 2015-12-20 | Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) | Способ диагностики и мониторинга онкологических заболеваний с использованием экзосом крови |
US10266895B2 (en) | 2014-11-05 | 2019-04-23 | Hitachi Chemical Company Ltd. | Exosomes and microvesicles in intestinal luminal fluids and stool and use of same for the assessment of inflammatory bowel disease |
WO2016077537A1 (en) | 2014-11-12 | 2016-05-19 | Hitachi Chemical Co., Ltd. | Method and device for diagnosing organ injury |
US11079378B2 (en) | 2014-12-10 | 2021-08-03 | Xpecting Diagnostics, Inc. | Detection of analytes in bodily fluid to determine the initiation of parturition |
EP3250706A4 (de) * | 2015-01-30 | 2018-09-05 | The Johns Hopkins University | Extrazelluläre vesikel zur wirkstoffverabreichung |
WO2016140388A1 (ko) * | 2015-03-05 | 2016-09-09 | 경북대학교 산학협력단 | 엑소좀 또는 이의 단백질을 포함하는 장기 독성 진단용 바이오마커 조성물 및 이를 이용한 진단 방법 |
US10071133B2 (en) * | 2015-03-12 | 2018-09-11 | Mitsui Chemicals, Inc. | Method for destroying exosomes, kit for destroying exosomes, and method for isolating exosomes derived from normal cells |
GB201504772D0 (en) * | 2015-03-20 | 2015-05-06 | Univ Aston | Preeclampsia |
US20160320390A1 (en) * | 2015-05-01 | 2016-11-03 | Morehouse School Of Medicine | Compositions and methods for capturing exosomes |
WO2016186215A1 (ja) * | 2015-05-20 | 2016-11-24 | Jsr株式会社 | 分離方法、検出方法、シグナル測定方法、疾患の判定方法、薬効評価方法、キット、液状組成物及び検体希釈液 |
EP3307243A4 (de) | 2015-06-09 | 2019-01-02 | The Board of Regents of The University of Texas System | Diagnostischer test für krebs im frühstadium |
US20180177727A1 (en) | 2015-06-10 | 2018-06-28 | Board Of Regents, The University Of Texas System | Use of exosomes for the treatment of disease |
WO2016201220A1 (en) * | 2015-06-10 | 2016-12-15 | Children's National Medical Center | Adipocyte-derived exosomes, and compositions, kits, and methods of using the same for detection and screening |
CN106319031A (zh) * | 2015-06-23 | 2017-01-11 | 上海市计划生育科学研究所 | 反复自然流产相关微小rna及其应用 |
EP3314027A4 (de) | 2015-06-29 | 2019-07-03 | Caris Science, Inc. | Therapeutische oligonukleotide |
CA2993652A1 (en) | 2015-07-28 | 2017-02-02 | Caris Science, Inc. | Targeted oligonucleotides |
JP6624704B2 (ja) | 2015-08-31 | 2019-12-25 | 日立化成株式会社 | 尿路上皮疾患の評価のための分子法 |
US11180810B2 (en) | 2015-09-29 | 2021-11-23 | Research Institute At Nationwide Children's Hospital | Methods for detecting hepatic fibrosis and responsiveness to therapy |
KR101695347B1 (ko) * | 2015-10-12 | 2017-01-11 | 이화여자대학교 산학협력단 | 유전자의 CpG 메틸화 변화를 이용한 조산 위험성 예측용 조성물 및 이의 이용 |
US10975436B2 (en) | 2016-01-05 | 2021-04-13 | Diamir, Llc | Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders |
WO2017124000A1 (en) | 2016-01-14 | 2017-07-20 | The Regents Of The University Of California | 3d-exoquant method for the analysis of surface molecules and quantification of tissue-specific exosomes in biological fluids |
EP3430137A4 (de) | 2016-03-18 | 2019-11-06 | Caris Science, Inc. | Oligonukleotidsonden und verwendungen davon |
US11149313B2 (en) | 2016-03-21 | 2021-10-19 | Diamir, Llc | Methods of using miRNAs from bodily fluids for detection and differentiation of neurodegenerative diseases |
CA3025486A1 (en) | 2016-05-25 | 2017-11-30 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
EP3472201A4 (de) * | 2016-06-20 | 2020-05-13 | Healthtell Inc. | Verfahren zur differentiellen diagnose von autoimmunerkrankungen |
WO2017223117A1 (en) | 2016-06-20 | 2017-12-28 | Healthtell Inc. | Methods for diagnosis and treatment of autoimmune diseases |
JP6980219B2 (ja) * | 2016-08-22 | 2021-12-15 | いであ株式会社 | がんを検出、又はがんの進行期を判定する方法 |
CN106282360B (zh) * | 2016-08-31 | 2019-11-08 | 武汉博杰生物医学科技有限公司 | 一种用于结肠癌预测转移的血浆miRNA组合、其探针组合物及应用 |
CN108473973A (zh) | 2016-09-30 | 2018-08-31 | 赛尔莱克斯生命科学公司 | 包含负载蛋白的外泌体的组合物以及制备和递送该组合物的方法 |
WO2018071806A1 (en) * | 2016-10-13 | 2018-04-19 | University Of Louisville Research Foundation, Inc. | Exosomal biomarkers for diagnosis and prognosis of cancer and related methods |
CN106282387A (zh) * | 2016-10-17 | 2017-01-04 | 上海赛安生物医药科技有限公司 | 胃癌检测引物探针及其试剂盒 |
CA3043264A1 (en) | 2016-11-11 | 2018-05-17 | Healthtell Inc. | Methods for identifying candidate biomarkers |
EP3541827A4 (de) * | 2016-11-11 | 2020-05-13 | University of Tennessee Research Foundation | Biomarker für frühe embryonale lebensfähigkeit und verfahren dafür |
EP3577214A4 (de) | 2017-02-06 | 2021-03-24 | Goetzl, Edward, J. | Von endothelzellen abgeleitete exosomen und deren verwendungen |
US11746381B2 (en) | 2017-03-10 | 2023-09-05 | Cancer Diagnostics Research Innvovations, LLC | Methods for diagnosing and treating gastric cancer using miRNA expression |
WO2018170624A1 (zh) * | 2017-03-18 | 2018-09-27 | 深圳市博奥康生物科技有限公司 | 降低微小rna-185和微小rna-424表达的方法 |
JP7083818B2 (ja) * | 2017-04-28 | 2022-06-13 | 一丸ファルコス株式会社 | プラセンタ抽出物 |
CA3065999A1 (en) * | 2017-05-24 | 2018-11-29 | Nanosomix, Inc. | Detection of biomarkers on vesicles for the diagnosis and prognosis of diseases and disorders |
CN107243012B (zh) * | 2017-05-25 | 2020-01-24 | 江苏大学 | 一种exosomes装载的miR-93-5p在治疗类风湿性关节炎中的应用 |
WO2019008414A1 (en) * | 2017-07-05 | 2019-01-10 | Datar Rajan | GENE EXPRESSION ANALYSIS BASED ON EXOSOMES FOR THE CARE OF CANCER |
US11899024B2 (en) | 2017-07-12 | 2024-02-13 | Exosome Diagnostics, Inc. | Treatment and diagnosis of parkinson's disease using isolated and enriched populations of biofluid-derived extracellular vesicles |
US10781487B2 (en) | 2017-07-24 | 2020-09-22 | Diamir, Llc | miRNA-based methods for detecting and monitoring aging |
CN107365852B (zh) * | 2017-08-14 | 2021-08-13 | 江苏为真生物医药技术股份有限公司 | 血清外泌体中肺癌相关microRNA分子标记的应用及其检测试剂盒 |
KR102109921B1 (ko) * | 2017-09-27 | 2020-05-12 | ㈜로제타엑소좀 | 크기 배제 크로마토그래피를 이용한 세포밖 소포체의 순도 분석 방법 |
WO2019094727A1 (en) * | 2017-11-10 | 2019-05-16 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing and treating cancer |
US12036262B2 (en) | 2017-11-22 | 2024-07-16 | University Of Louisville Research Foundation, Inc. | Edible plant-derived nanoparticles for regulation of gut microbiota |
KR102184911B1 (ko) * | 2019-06-07 | 2020-12-01 | 한림대학교 산학협력단 | miR-548을 함유하는 조산 예방 또는 치료제 조성물 |
US20220275455A1 (en) * | 2019-07-08 | 2022-09-01 | Preferred Networks, Inc. | Data processing and classification for determining a likelihood score for breast disease |
CN110747268B (zh) * | 2019-10-23 | 2023-02-03 | 华南农业大学 | 一种血清外泌体ssc-miR-17-5p作为母猪早期妊娠诊断分子标志物的应用 |
CN110878341A (zh) * | 2019-12-18 | 2020-03-13 | 苏州绘真医学检验有限公司 | 一种检测血液外泌体miRNA的引物组、试剂盒及方法 |
KR102242639B1 (ko) * | 2020-01-28 | 2021-04-21 | 고려대학교 산학협력단 | 간 섬유화 진단용 바이오마커 miRNA4668-5p |
US11211144B2 (en) | 2020-02-18 | 2021-12-28 | Tempus Labs, Inc. | Methods and systems for refining copy number variation in a liquid biopsy assay |
US11211147B2 (en) | 2020-02-18 | 2021-12-28 | Tempus Labs, Inc. | Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing |
US11475981B2 (en) | 2020-02-18 | 2022-10-18 | Tempus Labs, Inc. | Methods and systems for dynamic variant thresholding in a liquid biopsy assay |
RU2769927C2 (ru) * | 2020-02-28 | 2022-04-08 | Общество с ограниченной ответственностью "МедФлорина" | Способ диагностики меланомы с помощью экзосомальных микроРНК |
WO2021195154A1 (en) * | 2020-03-23 | 2021-09-30 | Avem Holdings, Llc | Isolation and purification of exosomes for regenerative medicine |
WO2022066617A1 (en) * | 2020-09-23 | 2022-03-31 | Ewinger, Inc. | Reagents, methods and kits for identifying pregnant human beings at risk for placental bed disorder(s) |
CN112575088B (zh) * | 2020-12-29 | 2022-07-05 | 浙江大学医学院附属妇产科医院 | 一种血浆外泌体miRNA生物标记物及其应用 |
WO2022204378A2 (en) * | 2021-03-24 | 2022-09-29 | City Of Hope | Identification of rna biomarkers in colorectal cancer |
WO2022216765A1 (en) * | 2021-04-07 | 2022-10-13 | Trustees Of Boston University | Exosome-based cancer assays |
CN113736877A (zh) * | 2021-10-15 | 2021-12-03 | 青岛大学附属医院 | 基于微小RNA 27a的子痫前期诊断用途及组合物 |
WO2024050519A2 (en) * | 2022-09-02 | 2024-03-07 | Ohio State Innovation Foundation | Methods and compositions for detecting cancer using exosomal proteins |
CN117802235A (zh) * | 2022-09-30 | 2024-04-02 | 上海思路迪生物医学科技有限公司 | 血液胞外囊泡miRNA在卵巢癌诊断中的应用 |
KR20240058548A (ko) * | 2022-10-26 | 2024-05-07 | 연세대학교 산학협력단 | 유방암 진단 또는 재발 예측을 위한 세포외 소포체 유래 miRNA 유전자 바이오마커 및 이의 용도 |
CN116855614A (zh) * | 2023-07-17 | 2023-10-10 | 宁夏大学 | 用于黄牛早期妊娠诊断的miRNA标志物及其应用 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5089181A (en) | 1987-02-24 | 1992-02-18 | Vestar, Inc. | Method of dehydrating vesicle preparations for long term storage |
US5449754A (en) | 1991-08-07 | 1995-09-12 | H & N Instruments, Inc. | Generation of combinatorial libraries |
US6015880A (en) | 1994-03-16 | 2000-01-18 | California Institute Of Technology | Method and substrate for performing multiple sequential reactions on a matrix |
US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
CA2284211A1 (en) | 1997-03-20 | 1998-09-24 | University Of Washington | Solvent for biopolymer synthesis, solvent microdroplets and methods of use |
US6242266B1 (en) | 1999-04-30 | 2001-06-05 | Agilent Technologies Inc. | Preparation of biopolymer arrays |
US6180351B1 (en) | 1999-07-22 | 2001-01-30 | Agilent Technologies Inc. | Chemical array fabrication with identifier |
US6232072B1 (en) | 1999-10-15 | 2001-05-15 | Agilent Technologies, Inc. | Biopolymer array inspection |
US6171797B1 (en) | 1999-10-20 | 2001-01-09 | Agilent Technologies Inc. | Methods of making polymeric arrays |
US6812023B1 (en) | 2000-04-27 | 2004-11-02 | Anosys, Inc. | Methods of producing membrane vesicles |
JP2002330055A (ja) * | 2001-04-27 | 2002-11-15 | Tdk Corp | 表面弾性波フィルタ、表面弾性波フィルタ用パッケージ及び表面弾性波フィルタモジュール |
US20030036077A1 (en) | 2001-05-31 | 2003-02-20 | Chronix Biomedical | Methods for generating an mRNA expression profile from an ecellular mRNA containing blood sample and using the same to identify functional state markers |
AU2002314957A1 (en) | 2001-06-06 | 2002-12-16 | Proteologics, Inc. | Methods and compositions related to tagging of membrane surface proteins |
CN1753993A (zh) * | 2002-12-18 | 2006-03-29 | 第三次浪潮技术公司 | 小核酸的检测 |
WO2005114192A1 (en) | 2004-05-13 | 2005-12-01 | Centre National De La Recherche Scientifique | A device for binding a target entity to a bait entity and detection methods using the same |
US8021847B2 (en) | 2004-06-02 | 2011-09-20 | Proxy Life Science Holdings, Inc. | Microvesicle-based compositions and methods |
CA2609260A1 (en) | 2004-06-02 | 2005-12-22 | Sourcepharm, Inc. | Rna-containing microvesicles and methods therefor |
EP1774015A4 (de) * | 2004-07-09 | 2009-01-21 | Chronix Biomedical Inc | Nachweis von nukleinsäuren zur beurteilung des risikos von bse (bovine spongiform encephalopathy) |
US9164108B2 (en) | 2005-03-22 | 2015-10-20 | Sri International | Liposome-based microarray and methods of use thereof |
WO2006119365A2 (en) * | 2005-05-02 | 2006-11-09 | Cold Spring Harbor Laboratory | Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster |
US20090011428A1 (en) | 2006-01-18 | 2009-01-08 | The Regents Of The University Of California | Fluid Membrane-Based Ligand Display System for Live Cell Assays and Disease Diagnosis Applications |
AU2008207746B2 (en) | 2007-01-26 | 2013-09-05 | University Of Louisville Research Foundation, Inc. | Methods of detecting autoantibodies for diagnosing and characterizing disorders |
AU2008207735B2 (en) | 2007-01-26 | 2013-10-03 | University Of Louisville Research Foundation, Inc. | Modification of exosomal components for use as a vaccine |
EP2613149B1 (de) * | 2007-07-25 | 2014-09-17 | University Of Louisville Research Foundation, Inc. | Exosomassoziierte microRNA als Diagnosemarker |
ES2419129T3 (es) | 2007-09-14 | 2013-08-19 | The Ohio State University Research Foundation | Expresión de miARN en microvesículas de sangre periférica humana y usos del mismo |
CN107254538A (zh) | 2008-11-12 | 2017-10-17 | 卡里斯生命科学瑞士控股有限责任公司 | 使用外来体来确定表现型的方法和系统 |
US20130288258A1 (en) * | 2012-04-27 | 2013-10-31 | University Of Louisville Research Foundation, Inc. | METHODS AND COMPOSITIONS FOR DETECTING COLORECTAL CANCER USING MICRO RNAs |
-
2008
- 2008-07-25 EP EP13162506.3A patent/EP2613149B1/de active Active
- 2008-07-25 ES ES08796656T patent/ES2420973T3/es active Active
- 2008-07-25 US US12/524,462 patent/US8216784B2/en active Active
- 2008-07-25 JP JP2010518421A patent/JP5156829B2/ja active Active
- 2008-07-25 EP EP14180889.9A patent/EP2806273B1/de active Active
- 2008-07-25 EP EP08796656.0A patent/EP2181332B1/de active Active
- 2008-07-25 CN CN2013101656263A patent/CN103276062A/zh active Pending
- 2008-07-25 WO PCT/US2008/071235 patent/WO2009015357A1/en active Application Filing
- 2008-07-25 CN CN200880025224.0A patent/CN101755208B/zh active Active
- 2008-07-25 GB GB0914442.9A patent/GB2459228B/en active Active
- 2008-07-25 AU AU2008279016A patent/AU2008279016B2/en active Active
- 2008-07-25 BR BRPI0807318A patent/BRPI0807318B8/pt active IP Right Grant
- 2008-07-25 CA CA2676113A patent/CA2676113C/en active Active
-
2009
- 2009-07-23 IL IL200028A patent/IL200028A/en active IP Right Grant
-
2010
- 2010-02-24 US US12/711,499 patent/US8637254B2/en active Active
-
2012
- 2012-06-06 US US13/489,686 patent/US20120238467A1/en not_active Abandoned
- 2012-12-10 JP JP2012269463A patent/JP5291241B2/ja active Active
-
2013
- 2013-04-05 JP JP2013079686A patent/JP5383940B2/ja active Active
-
2015
- 2015-10-29 IL IL242337A patent/IL242337A/en active IP Right Grant
-
2016
- 2016-12-16 US US15/381,668 patent/US20170137892A1/en not_active Abandoned
-
2017
- 2017-04-30 IL IL252040A patent/IL252040B/en active IP Right Grant
-
2018
- 2018-11-19 US US16/195,274 patent/US20190085410A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105368931A (zh) * | 2015-10-15 | 2016-03-02 | 天津市泌尿外科研究所 | 尿液中exosome源性miRNAs生物标记物的检测方法 |
CN108753964A (zh) * | 2018-06-04 | 2018-11-06 | 谢丽 | 一种用于非小细胞肺癌诊断及转移预警的试剂盒 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103276062A (zh) | 作为诊断标记物的外来体相关微rna | |
CN103842522A (zh) | 微rna生物标记物 | |
Stockdale et al. | Heart regeneration in the Mexican cavefish | |
Jahani et al. | Circular RNA; a new biomarker for breast cancer: A systematic review | |
Sánchez et al. | Exosomes from bulk and stem cells from human prostate cancer have a differential microRNA content that contributes cooperatively over local and pre-metastatic niche | |
Turashvili et al. | Novel prognostic and predictive microRNA targets for triple‐negative breast cancer | |
US9458510B2 (en) | Signatures and determinants associated with prostate cancer progression and methods of use thereof | |
WO2014160032A1 (en) | Exosome-associated rna as a diagnostic marker | |
Liu et al. | Diagnostic role of extracellular vesicles in cancer: a comprehensive systematic review and meta-analysis | |
Riggio et al. | The enigmatic role of RUNX 1 in female‐related cancers–current knowledge & future perspectives | |
US20200063208A1 (en) | Exosomal biomarkers for diagnosis and prognosis of cancer and related methods | |
Belair et al. | DGCR 8 is essential for tumor progression following PTEN loss in the prostate | |
CN102839179B (zh) | 一种鉴别肺癌亚型的microRNA标志物及其应用 | |
JP2013510575A (ja) | 卵丘細胞が差示発現する遺伝子およびそれらを用いる妊娠受容能をもつ卵母細胞の同定のためのアッセイ | |
EP2550534B1 (de) | Prognose von ösophagealem und gastroösophagealem gelenkkrebs | |
Kiba et al. | Differential micro ribonucleic acid expression profiling in ovarian endometrioma with leuprolide acetate treatment | |
CN107299129A (zh) | 循环核酸作为乳腺癌生物标志物的应用 | |
CN114582509A (zh) | 一种葡萄膜黑色素瘤预后风险评分模型及其应用 | |
Zhu et al. | MAL suppresses OSCC tumorigenesis by maintaining epithelial cell differentiation | |
Liu et al. | Single‐nucleus transcriptomics and chromatin accessibility analysis of musk gland development in Chinese forest musk deer (Moschus berezovskii) | |
Lai et al. | Selection of a malignant subpopulation from a colorectal cancer cell line | |
Ayoub et al. | Non-coding RNA Research | |
Fierro-González et al. | Metallomics | |
Nwachokor | SERUM EXOSOMAL MICRORNAS AS CLINICAL BIOMARKERS FOR THE DETECTION OF BARRETT’S ESOPHAGUS AND ESOPHAGEAL ADENOCARCINOMA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130904 |